Table 2.
Clinical trials for pro-angiogenic peptide vaccines.
| Antigen and type of peptide | Cancer type | Adjuvant used | Positive CTL response | Clinical response | Phase | HLA restriction | Combination | References |
|---|---|---|---|---|---|---|---|---|
| Monotherapy | ||||||||
| VEGFR2-169 (9 aa) |
Advance pancreatic cancer | Montanide ISA-51 | 11/18 (61%) | DCR 67% | I | A2402 | Gemcitabine | (67) |
| VEGFR1-770 or VEGFR1-1084 (9 aa each): |
Metastatic renal cell carcinoma | Montanide ISA-51 | 8/18 (83%) | SD (over 5 months)−8/18 (45%); PR−2/18 (11%) | I | A2402, A0201 | None | (68) |
| Multiple epitope vaccines | ||||||||
| VEGFR1-1084 and VEGFR2-169 (9 aa each) |
Advanced gliomas | Montanide ISA-51 | 7/8 (87/5%) to VEGFR1, 1/8 (12.5%) to VEGFR2 | SD−25% (2/6) PD— 75% (6/8) |
I | A2402 | None | (69) |
| VEGFR1-1084 and VEGFR2-169 (9 aa each) |
Advanced gastric cancer | Montanide ISA-51 | 18/22 (84%) to each of the peptides | PR−12/22 (55%) SD−10/22 (45%) DCR−100% |
I/II | A2402 | S-I and cisplatin | (70) |
| VEGFR1-1084, VEGFR2-169, RNF43-721, TOMM34-299, KOC1-508 (9–10 aa each) |
Advances Coloreactal cancer (CRC) | Montanide ISA-51 | 18/18 (100%) to at least one of the peptides 10/18 (55%) to VEGFR1, 12/18 (66%) to VEGFR2 |
CR-1/18 (5.5%) SD-6/18 (33%) DCR 38.9% |
I | A2402 | None | (71) |
| VEGFR1-1084, VEGFR2-169, KIF20A-66 (9–10 aa each) |
Resected pancreatic cancer | Montanide ISA-51 | 13/29 (44.8%) to VEGFR1 13/29 (44.8%) to VEGFR2 |
Median DFS of 15.8 months relative to 12 month of controls (only gemcitabine). | II | A2402 | Gemcitabine | (72) |
| VEGFR1-1084, VEGFR2-169, KIF20A-66 (9–10 aa each) |
Advanced pancreatic cancer | Montanide ISA-51 | 22/37 (59%) to VEGFR1 16/37 (43%) to VEGFR2 |
RR-12.1% PR-8/66 (12%) SD-41/66 (62%) DCR-74.2% |
II | A2402 | Gemcitabine | (73) |
| DEPDC1-294, URLC10-177, FoxM1-262, KIF20A-66, VEGERI-1084 (9–10 aa each) |
Advanced gastric cancer | Montanide ISA-51 | 11/20 (55%) to VEGFR1 | SD−10/22 (45%) PD−12/22 (55%) |
II | A2402 | None | (74) |
CR, complete response; SD, stable disease; PR, partial response; PD, progressive disease; DFS, disease-free survival; DCR, disease control rate (usually SD + PR).